Analysts Offer Predictions for CVKD Q1 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Research analysts at Noble Financial issued their Q1 2025 EPS estimates for shares of Cadrenal Therapeutics in a report issued on Friday, November 8th. Noble Financial analyst R. Leboyer forecasts that the company will earn ($2.15) per share for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($6.72) per share. Noble Financial also issued estimates for Cadrenal Therapeutics’ Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.39) EPS and Q4 2025 earnings at ($1.42) EPS.

Separately, HC Wainwright upped their price target on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday.

Cadrenal Therapeutics Stock Down 0.9 %

Cadrenal Therapeutics stock opened at $17.73 on Monday. The stock has a fifty day simple moving average of $13.09. Cadrenal Therapeutics has a 52-week low of $5.40 and a 52-week high of $32.55. The firm has a market capitalization of $18.94 million, a price-to-earnings ratio of -2.68 and a beta of 1.52.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.